Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis
The advent of new chemotherapeutic and immunotherapeutic treatments has markedly improved outcomes in patients with cancer. However, increasing numbers of elderly patients with cancer and prolonged periods of treatment have made the management of cardiovascular complications and treatment-induced ca...
Gespeichert in:
| Veröffentlicht in: | Journal of Atherosclerosis and Thrombosis 2018/10/01, Vol.25(10), pp.994-1002 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1002 |
|---|---|
| container_issue | 10 |
| container_start_page | 994 |
| container_title | Journal of Atherosclerosis and Thrombosis |
| container_volume | 25 |
| creator | Mukai, Mikio Komori, Keiko Oka, Toru |
| description | The advent of new chemotherapeutic and immunotherapeutic treatments has markedly improved outcomes in patients with cancer. However, increasing numbers of elderly patients with cancer and prolonged periods of treatment have made the management of cardiovascular complications and treatment-induced cardiotoxicity an important concern, and onco-cardiology has received increasing attention. The number of patients with cardiotoxicity, particularly atherosclerotic lesions, and the usage of angiogenesis inhibitors have increased, making the involvement of onco-cardiologists essential for effective disease management. A paradigm shift in immunotherapy was caused by the development of immune checkpoint inhibitors. Because vascular endothelial growth factors (VEGF) in the cancer microenvironment and cancer immune function are interrelated angiogenesis inhibitors will most likely play an increasingly important role in combined immunotherapy. To ensure the optimal long-term diagnosis and long-term treatment of cancer and the effective management of treatment-related atherosclerotic diseases, the long-term continuous participation of onco-cardiologists is essential. |
| doi_str_mv | 10.5551/jat.RV17027 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6193189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30224607</sourcerecordid><originalsourceid>FETCH-LOGICAL-c651t-44e921771c0805f641b10d4e8c1d4b78395775487e21d418e93a9a85c8496aed3</originalsourceid><addsrcrecordid>eNpVUU1rGzEQFaWl-eop97D3solGHyvpUkhN4gQSCiHpVcjacbxmV2u061L_-4xjx7QXzTDz9N7jDWPnwC-11nC1DOPl028wXJhP7Bis5aW0Rn6mXirqlbFH7GQYlpxLqbX4yo4kF0JV3Byz6SPGRUjN0BUh1cVjSOEVO0xj0c-LSUgRczFZYNePC8xhtSnvU72OWBfX20E_xHb7NsMZ-zIP7YDf9vWUvdzePE_uyodf0_vJ9UMZKw1jqRQ6AcZA5JbreaVgBrxWaCPUamasdNoYraxBQQOw6GRwwepolasC1vKU_djxrtazDutITnNo_So3Xcgb34fG_79JzcK_9n98BU6CdUTwfUcQyfeQcX74C9xv8_SUp9_nSeiLf-UO2I8ACTDdAWjbxND2qW0S-mW_zoly8PjX1H23CV5wsJ5zoUmGiufOKZLkQoJRAEBMP3dMy2GkGxykQh4bSvndltBbl_Tu_R2WdMPsMck3pN2fyA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Mukai, Mikio ; Komori, Keiko ; Oka, Toru</creator><creatorcontrib>Mukai, Mikio ; Komori, Keiko ; Oka, Toru ; Osaka International Cancer Institute ; Department of Pharmacy ; Osaka Women's and Children's Hospital ; Department of Medical Checkup ; Osaka Prefectural Hospital Organization ; Onco-Cardiology Unit</creatorcontrib><description>The advent of new chemotherapeutic and immunotherapeutic treatments has markedly improved outcomes in patients with cancer. However, increasing numbers of elderly patients with cancer and prolonged periods of treatment have made the management of cardiovascular complications and treatment-induced cardiotoxicity an important concern, and onco-cardiology has received increasing attention. The number of patients with cardiotoxicity, particularly atherosclerotic lesions, and the usage of angiogenesis inhibitors have increased, making the involvement of onco-cardiologists essential for effective disease management. A paradigm shift in immunotherapy was caused by the development of immune checkpoint inhibitors. Because vascular endothelial growth factors (VEGF) in the cancer microenvironment and cancer immune function are interrelated angiogenesis inhibitors will most likely play an increasingly important role in combined immunotherapy. To ensure the optimal long-term diagnosis and long-term treatment of cancer and the effective management of treatment-related atherosclerotic diseases, the long-term continuous participation of onco-cardiologists is essential.</description><identifier>ISSN: 1340-3478</identifier><identifier>EISSN: 1880-3873</identifier><identifier>DOI: 10.5551/jat.RV17027</identifier><identifier>PMID: 30224607</identifier><language>eng</language><publisher>Japan: Japan Atherosclerosis Society</publisher><subject>Animals ; Antineoplastic Agents - adverse effects ; Atherosclerosis ; Atherosclerosis - chemically induced ; Atherosclerosis - prevention & control ; Cancer ; Cardiotoxicity ; Disease Management ; Humans ; Immune checkpoint inhibitors ; Neoplasms - drug therapy ; Prognosis ; Review ; Vascular endothelial growth factors</subject><ispartof>Journal of Atherosclerosis and Thrombosis, 2018/10/01, Vol.25(10), pp.994-1002</ispartof><rights>2018 This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.</rights><rights>2018 Japan Atherosclerosis Society 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c651t-44e921771c0805f641b10d4e8c1d4b78395775487e21d418e93a9a85c8496aed3</citedby><cites>FETCH-LOGICAL-c651t-44e921771c0805f641b10d4e8c1d4b78395775487e21d418e93a9a85c8496aed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193189/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193189/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1881,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30224607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mukai, Mikio</creatorcontrib><creatorcontrib>Komori, Keiko</creatorcontrib><creatorcontrib>Oka, Toru</creatorcontrib><creatorcontrib>Osaka International Cancer Institute</creatorcontrib><creatorcontrib>Department of Pharmacy</creatorcontrib><creatorcontrib>Osaka Women's and Children's Hospital</creatorcontrib><creatorcontrib>Department of Medical Checkup</creatorcontrib><creatorcontrib>Osaka Prefectural Hospital Organization</creatorcontrib><creatorcontrib>Onco-Cardiology Unit</creatorcontrib><title>Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis</title><title>Journal of Atherosclerosis and Thrombosis</title><addtitle>JAT</addtitle><description>The advent of new chemotherapeutic and immunotherapeutic treatments has markedly improved outcomes in patients with cancer. However, increasing numbers of elderly patients with cancer and prolonged periods of treatment have made the management of cardiovascular complications and treatment-induced cardiotoxicity an important concern, and onco-cardiology has received increasing attention. The number of patients with cardiotoxicity, particularly atherosclerotic lesions, and the usage of angiogenesis inhibitors have increased, making the involvement of onco-cardiologists essential for effective disease management. A paradigm shift in immunotherapy was caused by the development of immune checkpoint inhibitors. Because vascular endothelial growth factors (VEGF) in the cancer microenvironment and cancer immune function are interrelated angiogenesis inhibitors will most likely play an increasingly important role in combined immunotherapy. To ensure the optimal long-term diagnosis and long-term treatment of cancer and the effective management of treatment-related atherosclerotic diseases, the long-term continuous participation of onco-cardiologists is essential.</description><subject>Animals</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis - chemically induced</subject><subject>Atherosclerosis - prevention & control</subject><subject>Cancer</subject><subject>Cardiotoxicity</subject><subject>Disease Management</subject><subject>Humans</subject><subject>Immune checkpoint inhibitors</subject><subject>Neoplasms - drug therapy</subject><subject>Prognosis</subject><subject>Review</subject><subject>Vascular endothelial growth factors</subject><issn>1340-3478</issn><issn>1880-3873</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUU1rGzEQFaWl-eop97D3solGHyvpUkhN4gQSCiHpVcjacbxmV2u061L_-4xjx7QXzTDz9N7jDWPnwC-11nC1DOPl028wXJhP7Bis5aW0Rn6mXirqlbFH7GQYlpxLqbX4yo4kF0JV3Byz6SPGRUjN0BUh1cVjSOEVO0xj0c-LSUgRczFZYNePC8xhtSnvU72OWBfX20E_xHb7NsMZ-zIP7YDf9vWUvdzePE_uyodf0_vJ9UMZKw1jqRQ6AcZA5JbreaVgBrxWaCPUamasdNoYraxBQQOw6GRwwepolasC1vKU_djxrtazDutITnNo_So3Xcgb34fG_79JzcK_9n98BU6CdUTwfUcQyfeQcX74C9xv8_SUp9_nSeiLf-UO2I8ACTDdAWjbxND2qW0S-mW_zoly8PjX1H23CV5wsJ5zoUmGiufOKZLkQoJRAEBMP3dMy2GkGxykQh4bSvndltBbl_Tu_R2WdMPsMck3pN2fyA</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Mukai, Mikio</creator><creator>Komori, Keiko</creator><creator>Oka, Toru</creator><general>Japan Atherosclerosis Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20181001</creationdate><title>Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis</title><author>Mukai, Mikio ; Komori, Keiko ; Oka, Toru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c651t-44e921771c0805f641b10d4e8c1d4b78395775487e21d418e93a9a85c8496aed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis - chemically induced</topic><topic>Atherosclerosis - prevention & control</topic><topic>Cancer</topic><topic>Cardiotoxicity</topic><topic>Disease Management</topic><topic>Humans</topic><topic>Immune checkpoint inhibitors</topic><topic>Neoplasms - drug therapy</topic><topic>Prognosis</topic><topic>Review</topic><topic>Vascular endothelial growth factors</topic><toplevel>online_resources</toplevel><creatorcontrib>Mukai, Mikio</creatorcontrib><creatorcontrib>Komori, Keiko</creatorcontrib><creatorcontrib>Oka, Toru</creatorcontrib><creatorcontrib>Osaka International Cancer Institute</creatorcontrib><creatorcontrib>Department of Pharmacy</creatorcontrib><creatorcontrib>Osaka Women's and Children's Hospital</creatorcontrib><creatorcontrib>Department of Medical Checkup</creatorcontrib><creatorcontrib>Osaka Prefectural Hospital Organization</creatorcontrib><creatorcontrib>Onco-Cardiology Unit</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Atherosclerosis and Thrombosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mukai, Mikio</au><au>Komori, Keiko</au><au>Oka, Toru</au><aucorp>Osaka International Cancer Institute</aucorp><aucorp>Department of Pharmacy</aucorp><aucorp>Osaka Women's and Children's Hospital</aucorp><aucorp>Department of Medical Checkup</aucorp><aucorp>Osaka Prefectural Hospital Organization</aucorp><aucorp>Onco-Cardiology Unit</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis</atitle><jtitle>Journal of Atherosclerosis and Thrombosis</jtitle><addtitle>JAT</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>25</volume><issue>10</issue><spage>994</spage><epage>1002</epage><pages>994-1002</pages><issn>1340-3478</issn><eissn>1880-3873</eissn><abstract>The advent of new chemotherapeutic and immunotherapeutic treatments has markedly improved outcomes in patients with cancer. However, increasing numbers of elderly patients with cancer and prolonged periods of treatment have made the management of cardiovascular complications and treatment-induced cardiotoxicity an important concern, and onco-cardiology has received increasing attention. The number of patients with cardiotoxicity, particularly atherosclerotic lesions, and the usage of angiogenesis inhibitors have increased, making the involvement of onco-cardiologists essential for effective disease management. A paradigm shift in immunotherapy was caused by the development of immune checkpoint inhibitors. Because vascular endothelial growth factors (VEGF) in the cancer microenvironment and cancer immune function are interrelated angiogenesis inhibitors will most likely play an increasingly important role in combined immunotherapy. To ensure the optimal long-term diagnosis and long-term treatment of cancer and the effective management of treatment-related atherosclerotic diseases, the long-term continuous participation of onco-cardiologists is essential.</abstract><cop>Japan</cop><pub>Japan Atherosclerosis Society</pub><pmid>30224607</pmid><doi>10.5551/jat.RV17027</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1340-3478 |
| ispartof | Journal of Atherosclerosis and Thrombosis, 2018/10/01, Vol.25(10), pp.994-1002 |
| issn | 1340-3478 1880-3873 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6193189 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Animals Antineoplastic Agents - adverse effects Atherosclerosis Atherosclerosis - chemically induced Atherosclerosis - prevention & control Cancer Cardiotoxicity Disease Management Humans Immune checkpoint inhibitors Neoplasms - drug therapy Prognosis Review Vascular endothelial growth factors |
| title | Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A25%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanism%20and%20Management%20of%20Cancer%20Chemotherapy-Induced%20Atherosclerosis&rft.jtitle=Journal%20of%20Atherosclerosis%20and%20Thrombosis&rft.au=Mukai,%20Mikio&rft.aucorp=Osaka%20International%20Cancer%20Institute&rft.date=2018-10-01&rft.volume=25&rft.issue=10&rft.spage=994&rft.epage=1002&rft.pages=994-1002&rft.issn=1340-3478&rft.eissn=1880-3873&rft_id=info:doi/10.5551/jat.RV17027&rft_dat=%3Cpubmed_cross%3E30224607%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30224607&rfr_iscdi=true |